| NCT06765109 | Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC | RECRUITING | PHASE3 | 2025-07-17 | 2029-12 | 2029-12 |
| NCT06521554 | A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1) | RECRUITING | PHASE1 | 2024-07-18 | 2026-03 | 2026-03 |
| NCT05384626 | A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) | RECRUITING | PHASE1, PHASE2 | 2022-06-09 | 2028-01 | 2027-12 |
| NCT05118789 | A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) | RECRUITING | PHASE1, PHASE2 | 2022-01-04 | 2026-10-31 | 2025-10-31 |